Skip to Content
Merck
CN

Mice expressing mutant Trpv4 recapitulate the human TRPV4 disorders.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research (2014-03-20)
Michael M Weinstein, Stuart W Tompson, Yuqing Chen, Brendan Lee, Daniel H Cohn
ABSTRACT

Activating mutations in transient receptor potential vanilloid family member 4 (Trpv4) are known to cause a spectrum of skeletal dysplasias ranging from autosomal dominant brachyolmia to lethal metatropic dysplasia. To develop an animal model of these disorders, we created transgenic mice expressing either wild-type or mutant TRPV4. Mice transgenic for wild-type Trpv4 showed no morphological changes at embryonic day 16.5 but did have a delay in bone mineralization. Overexpression of a mutant TRPV4 caused a lethal skeletal dysplasia that phenocopied many abnormalities associated with metatropic dysplasia in humans, including dumbbell-shaped long bones, a small ribcage, abnormalities in the autopod, and abnormal ossification in the vertebrae. The difference in phenotype between embryos transgenic for wild-type or mutant Trpv4 demonstrates that an increased amount of wild-type protein can be tolerated and that an activating mutation of this protein is required to produce a skeletal dysplasia phenotype.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-Collagen Type X Rabbit pAb, liquid, Calbiochem®